Replies to post #305441 on Bioelectronics Corp (BIEL)

[GetSeriousOK]

Cite the journal article that proved the ActiPatch was superior to "A Cox 2 Opiod."

Cite ANY of "the Opioid Studies For Biel [that] Have Been Posts Dozens Of Times."

And then tell Kelly to post them on the clinical evidence page of her website, because they're all conspicuous in their absence.

PLEASE don't paste any powerpoint slides or bar graphs or old quotes from Andy. CITE THE JOURNAL ARTICLE.

[ddls]

BIEL's a nothing burger, a dud, finished!

The BIEL sales-staff puts out plenty "false information."

Actually, down right lies!

147 times more sells than buys today and finished up 9% on a $23 buy at the close!

This is junk, pure and simple.

Declining Sales Cheers!~~

[Just No]

Speaking of false information.

Actipatch Was Superior To A Cox 2 Opioid Deemed To Strong

There is no such thing as a Cox-2 Opiod.

You seem to be referring to the Cervical Osteoarthritis study.
Pulsed Shortwave Therapy in Cervical Osteoarthritis: an NSAID- Controlled, Randomized Clinical Trial
https://link.springer.com/article/10.1007/s42399-020-00652-y
In that study, they compared ActiPatch to Arcoxia, an NSAID Cox-2 inhibitor not approved for use in the USA. Arcoxia is not an opioid.

They showed that ActiPatch was superior to Arcoxia, so that was good, but as has been pointed out, it doesn’t speak to opioid use specifically.

The argument that if it reduces one type of analgesic, it will work similarly with other types is worth making. Sometimes government agencies are unpredictable.

Does anyone else see the irony in putting so much hope on another government agency providing the impetus needed for BIEL’s success?

[GetSeriousOK]

the Opioid Studies For Biel Have Been Posts Dozens Of Times.

Cite just ONE of these opioid studies.

And then tell Kelly to post them on the clinical evidence page of her website, because they're all conspicuous in their absence.

PLEASE don't paste any powerpoint slides or bar graphs or old quotes from Andy. CITE THE JOURNAL ARTICLE.

And don't cite any of Ilfeld's case studies. BIEL needs a clinical trial, not a Case Study.

And don't cite Ilfeld's current active ActiPatch Pilot study because (a) it's just a PILOT STUDY and (b) There aren't any endpoints, primary or secondary, regarding opioid use. The Primary endpoints are all about VAS scores (Likert scale), and only one secondary endpoint (#11, see link below) is about analgesics -- ALL analgesics, not just opioids.

https://clinicaltrials.gov/ct2/show/NCT05392803?cond=Phantom+Pain&locn=San+Diego&draw=2&rank=5

Ilfeld appears to be planning some opioid use endpoints in future trials. He hasn't started any of those yet.